Tuberc Respir Dis 2017;80:105-112 www.e-trd.org monitor the response of treatment or therapeutic intervention 3 . PFTs should have acceptability and reproducibility 4 . The test technicians must ensure that subjects can undertake the test smoothly. Subjects must be instructed to meet the criteria of acceptability and reproducibility.
Spirometry is indicated for the following 5 . (1) Spirometry is used as a complementary tool for diagnosis of a disease. Therefore, spirometry helps make a diagnosis by differentiating between obstructive lung diseases, such as asthma or chronic obstructive pulmonary disease (COPD), and restrictive lung disorders, such as interstitial pneumonia. (2) Spirometry is used to identify respiratory impairment caused by occupational factors at an early stage. If the impairment is fixed, it provides objective data for the disability grade and its compensation. (3) Spirometry is used to evaluate the prognostic prospects or the response to treatment of a specific disease by serial tests. (4) Spirometry is used for preoperative evaluation to predict respiratory complications of surgery. (5) Spirometry is also used for management of national health. (6) Finally, spirometry is used for screening patients with pulmonary functional abnormalities among smokers.
The absolute contraindications of spirometry are patients with recent eye surgery, open heart surgery, laparotomy, stroke, cardiac arrest, myocardial infarction, pneumothorax, retinal detachment, and aortic aneurysm within 3 months. Other contraindications are patients with hyperventilation, diseases in which maximal ventilatory effort can be problematic (Moyamoya disease, repetitive spontaneous pneumothorax) or those with current respiratory infection, such as tuberculosis or their families were exposed to such infection, those with massive hemoptysis in the past 1 month, and those whose systolic blood pressure exceeds 200 mm Hg or diastolic blood pressure exceeds 140 mm Hg.
The relative contraindications of spirometry are patients with experience of urinary incontinence, those with chest or abdominal pain, those who have pain inside the mouth or on the face when biting the mouth piece, and those with dementia or decreased consciousness.
Test methods
Subjects should have accurate measurements of height and weight taken before spirometry. Additionally, the history of smoking, recent illness, and medications should be determined. Subjects are also asked whether they avoided any certain requests before the test, and they are asked to loosen tight clothing and to remove dentures 4, 6 . For the testing procedure, subjects are provided clear instructions and should be encouraged to breathe well following the instructions by each phase (Figure 1 ). At phase 1 of maximal inspiration, subjects are encouraged to take the deepest breath that they are able to. At phase 2 of the blast phase, subjects are asked to blast air into the spirometer as hard as possible, preferably for at least 6 seconds. At phase 3 of continuation, subjects are asked to maintain exhalation for at least 6 seconds (>3 seconds for children younger than 10 years old).
Subjects undergoing spirometry are asked to inhale the air quickly up to a total lung capacity (TLC) at once. Without any hesitation, subjects are then asked to exhale as hard as possible until they cannot exhale any longer. Thereafter, they inhale immediately as rapidly as possible. While conducting inhalation-exhalation with the maximum breathing capacity, a graph can be plotted with volume (X axis) and flow (Y axis), and this is called the flow-volume curve ( Figure 2 ).
Quality control

1) Acceptability
Acceptable spirometry testing needs to be conducted three times by an acceptable and reproducible method for determining forced vital capacity (FVC). FVC is obtained from a maximally forced expiratory effort. The tester must be able to verify the acceptability of the test. A testing method that is improperly conducted may be misinterpreted as a disease. Acceptability can be determined by direct confirmation on the flow-volume curve and the volume-time curve. An acceptable method is defined when the peak is sharp in the flowvolume curve and the exhalation time should be longer than 6 seconds in the volume-time curve. Two or three test curves satisfying acceptability are used for analysis.
2) Reproducibility
Reproducibility of the PFT is determined by comparing the values of FVC and forced expiratory volume at 1 second (FEV 1 ) between tests, and should meet the following criteria.
(1) The difference between the highest values of two FVCs should be within 5% or 150 mL. (2) When FVC is less than 1.0 L, the difference between the highest two values must be within 100 mL. (3) The difference between the two highest values of FEV 1 should also be within 150 mL. (4) The highest FVC and FEV 1 may be obtained from each different test 5, 7, 8 . Until the results of three tests meet the criteria of reproducibility, the test should be repeated up to eight times. When a subject cannot continue the test or does not want to do any more tests, and when good results are regarded as difficult to obtain, even if more tests are performed, the best three tests are selected (Figure 3 
3) Selection of test values
According to the method described above, the scores of spirometry are evaluated on the basis of acceptability and reproducibility. The selection criteria are shown in Table 1 .
Interpretation
Interpretation of spirometry should be clear, concise, and informative, but a simple description as normal or abnormal only is not helpful. Additionally, this test should have optimal quality before interpretation of spirometry.
Even when the result of the test is not appropriate, useful information about the patient may be provided. The interpreter should be aware of the potential problem of the test performed and the possible inaccuracy of the interpretation. Most inappropriately performed spirometry tests are due to test subject-related factors. Therefore, an appropriate test performance can be ensured by carefully observing the subjects and the volume-time curve, as well as the flow-volume curve, during the test. Additionally, when interpreting spirometry results, they should be considered together with the clinical findings of symptoms. Those include respiratory symptoms, such as cough and dyspnea, past medical history, smoking history, examination results, and chest radiology reports.
Generally, spirometry provides the following important information. (1) FVC is defined as the total expiratory volume from one time of a maximally forced expiration maneuver. (2) FEV 1 is defined as expiratory volume that has been exhaled at the end of the first second of a maximally forced expiration maneuver. However, when considering FEV 1 /FVC less than 0.7 as the baseline for obstructive ventilatory defects, because FEV 1 / FVC decreases as age increases, false-positivity is likely to occur. False-positivity can result in the wrong diagnosis for obstructive pulmonary disease in healthy, older subjects who have never been exposed to risk 12 . When the same criteria are applied to young subjects, they may be diagnosed as being normal, even though they have obstructive pulmonary disease 13 . Therefore, a reference point of obstructive lung disease in young subjects, if they have clinical symptoms and a medical history, can be increased to FEV 1 /FVC <0.75-0.80 13 .
To overcome these problems, the American Thoracic Society and the European Respiratory Society defined the value corresponding to the lower fifth percentile of spirometry in the same age normal group that is 95 percentile method as the criteria of ventilation disorders as the lower limit of normal 14 . The American Thoracic Society and European Respiratory Society also recommend using vital capacity (VC) instead of FVC in the interpretation of spirometry 14 . VC is generally measured as greater than FVC. Additionally, VC is more accurate than FVC when the airway is flexible, such as in the case of emphysema, because it can diagnose airway obstruction with more certainty. However, our guideline adopts FVC instead of VC for interpretation in most other guidelines because the measurement of VC at spirometer is impossible. Ventilatory disorders can be divided into three main types. Obstructive ventilatory disorders occur when maximum flow rate is reduced compared with maximal volume, FVC, during a forced exhalation maneuver due to airway obstruction. When FEV 1 / FVC is less than 0.7 in spirometry, it is interpreted as having obstructive ventilatory defects (Figure 4 ). For the initial stage of obstructive pulmonary disease, initial forced expiratory flow remains normal, but late forced expiratory flow is decreased. Therefore, in this situation, FEV 1 /FVC may be maintained as normal. FEV 1 is reduced when obstructive pulmonary disease further progresses causing severe airway obstruction. Representative diseases of obstructive pulmonary disease include asthma and COPD.
Restrictive ventilation disorders are characterized by a reduced TLC with normal FEV 1 /FVC (Figure 4) 14 . Pulmonary fibrosis, chest wall disease, or neuromuscular diseases can show restrictive ventilatory defects. Measurement of diffusing capacity is necessary to differentiate pulmonary parenchyma disease, chest wall disease, and neuromuscular disease.
Mixed ventilation disorders occur when obstructive and restrictive ventilatory defects occur together, in which FEV 1 / FVC decreases, as well as TLC. Obstructive or restrictive ventilatory defects can show a decrease in FVC from spirometry. Therefore, measurement of TLC is required to accurately determine the concurrence of restrictive and obstructive ventilatory defects (Figure 4 ). Mixed ventilatory defects are observed in fibrothorax accompanied by tuberculosis sequelae-induced airway obstruction or in smokers with COPD accompanied by pulmonary fibrosis.
PFT values in classification of lung function impairment show an association with daily life performance, severity of disease, and prognosis of patients with respiratory diseases. However, these values cannot predict exact symptoms or prognosis of individuals. When residual volume is increased, which leads to a reduction in FVC in obstructive pulmonary diseases, FEV 1 /FVC may not decrease at all. Therefore, FEV 1 / FVC helps to determine the presence of airway obstruction, but is not appropriate for identifying the severity of obstructive ventilation disorders.
To determine the severity of airway obstruction, a percentage of the predicted normal value of FEV 1 is used. The severity of obstructive pulmonary diseases is shown in Table 2 11,14-16 . The severity of restrictive ventilation disorders is related to the degree of pulmonary parenchyma disease and neuromuscular disease, but it cannot reflect the condition of the patient. Classification of the severity of restrictive ventilation disorders uses VC and TLC 17 . However, the American Thoracic Society and European Respiratory Society recommended using FEV 1 for classification of the severity of all ventilation impairment, including restrictive ventilation disorders, in 2005 (Table 3) .
It can be regarded as respiratory failure in severe chronic lung diseases if the patient has been diagnosed as an underlying pulmonary disease for more than 1 year and if the lung disability of the patient is fixed in spite of sufficient treatment over the past 2 months. Table 4 14,17 shows the Criteria for Pulmonary Disability-Grading system provided by the Ministry of Health and Welfare in 2015 18 . The descending curve of the normal air flow-volume curve forms a relatively straight line after reaching a peak. However, in obstructive pulmonary disease, the maximal forced expi- www.e-trd.org ratory flow rate is reduced and the descending curve shifts sharply downward with an increase in downward concavity after reaching the peak. Lung capacity is mainly reduced, but the airflow rate does not decrease much in restrictive ventilation disorders. Therefore, the flow-volume curve forms a tall and narrow shape. The maximal forced expiratory flow rate is relatively maintained, and the descending curve forms a straight line with a steep slope. If a plateau is formed from inhalation or exhalation in a flowvolume curve, stenosis of the upper airway or central airway is suspected. If this condition is clinically suspected, its progress should be observed and the airway should be evaluated. Also, further evaluation including imaging study and bronchoscopy is recommended in this situation.
Bronchodilator Test
The bronchodilator test is a method for measuring the changes in lung capacity after inhaling a short-acting bronchodilator drug that dilates the airway. When an obstructive ventilatory defect is observed, this test helps to diagnose and evaluate asthma and COPD by measuring reversibility induced by the bronchodilator drug 19 .
Test methods
The bronchodilator test is conducted to determine the reversibility of airflow limitation after administration of a shortacting bronchodilator drug as a part of PFTs. Selection of the type of drug, dosage, and the route of administration to be used at this time are decided in accordance with what needs to be obtained from the bronchodilator reversibility test. If the purpose of the bronchodilator reversibility test is to determine if addition of a new drug to the regulated treatment can improve lung function of the patient, medication should be administered on a regular basis before the test can be continued. However, if the purpose of this test is to determine the reversibility of airflow limitation, the test should be conducted after suspending the medication for a certain period.
Test procedure
In the albuterol (short-acting b 2 -bronchodilator) 19 bronchodilator test, the subject fully exhales slowly, and sprays an albuterol metered dose of 100 μg (1 puff) while biting a valved chamber. The subject then slowly and deeply inhales until reaching TLC over 3-5 seconds, holds the breath for 5-10 seconds, and exhales. This procedure is repeated four times (total 400 μg of albuterol), at intervals of 30 seconds. However, if there is any concern of affecting the pulse rate of the subject or causing occurrence of hand tremors, the dose may be decreased to 200 μg. After inhalation of the last medication, the spirometry test is conducted again between 10-20 minutes 20 .
Interpretation
A positive response to a bronchodilator is defined as follows.
(1) Generally, a positive response is defined as an increase of ≥12% and ≥200 mL as an absolute value compared with baseline in either FEV 1 or FVC. (2) When expressing a bronchodilator response with a percentage of the pre-inhalation indica- tor, it tends to be calculated as larger when the baseline value of VC is smaller, even if the amount of variation is the same. (3) When the bronchodilator response is positive, it suggests asthma in general. This conclusion is reached because the increase in post-inhalation flow rate and volume in patients with asthma is greater than that in patients with COPD. However, excluding COPD with the finding of a positive bronchodilator response only is difficult. Recent Global Initiative for Asthma-GOLD guidelines state that in the case of a large increase of ≥12% and ≥400 mL in FEV 1 after bronchodilator inhalation, the possibility of COPD is low, whereas the situation is more reasonable for asthma or asthma-COPD overlap syndrome 21 . Regardless of an increase in exhalation time after bronchodilator inhalation, when only FVC is increased (≥12% and ≥200 mL of the baseline), it may also be considered as a sign of bronchiectasis.
The information obtained from one time test can be useful with comparison with normal reference. However, performing a follow-up observation with repetitive spirometry, conducting treatment in specific individuals, and observation over time can provide clinically important information.
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